Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
IM-21 by Imunopharm Technology for Refractory Multiple Myeloma: Likelihood of Approval
IM-21 is under clinical development by Imunopharm Technology and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData,...